FDA allows world first vitiligo drug trial

A new treatment for one of the world’s most distressing skin disorders is about to commence trials across the USA and Europe. The USA’s Food and Drug Administration (FDA) has agreed to allow a pilot trial of the new drug SCENESSE®(afamelanotide) to determine whether it can help repigment the skin of patients with vitiligo.

Vitiligo is an autoimmune disease which causes patchy loss of skin color in ‘lesions’ which spread over the body. Onset of the disease can be sudden and lesions can spread quickly. Vitiligo affects all races but is most visible in individuals with darker skin. Global studies have shown vitiligo can have a significant impact upon an individual’s quality of life as their skin inexplicitly and dramatically changes color.

SCENESSE®, an injectable which mimics the body’s natural ability to activate the skin pigment melanin, will be trialled in nonsegmental vitiligo; the most common form of the disease which affects over 45 million individuals globally.